Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PMP22 | Q01453 | 2/20 | 0.86 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.86 |
| ▸ | BLM | P54132 | 1/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.86 |
| ▸ | GRM8 | O00222 | 2/20 | 0.82 |
| ▸ | GRM6 | O15303 | 2/20 | 0.82 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.82 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.82 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.82 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.82 |
| ▸ | GSR | P00390 | 1/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.82 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.82 |
| ▸ | GRM5 | P41594 | 1/20 | 0.82 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.82 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.82 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.82 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.82 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.82 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutamine SCHEMBL9165715 | 1.00 | PMP22 (0.86) | PMP22ALOX15BLMKMT2AGRM8 | |
| Glutamine SCHEMBL9276090 | 1.00 | PMP22 (0.86) | PMP22ALOX15BLMKMT2AGRM8 | |
| Glutamine SCHEMBL19878277 | 1.00 | PMP22 (0.86) | PMP22ALOX15BLMKMT2AGRM8 | |
| Glutamine SCHEMBL9276094 | 1.00 | PMP22 (0.86) | PMP22ALOX15BLMKMT2AGRM8 | |
| Glutamine SCHEMBL1634485 | 1.00 | PMP22 (0.86) | PMP22ALOX15BLMKMT2AGRM8 | |
| Glutamine SCHEMBL352340 | 1.00 | PMP22 (0.86) | PMP22ALOX15BLMKMT2AGRM8 | |
| Glutamine SCHEMBL8429219 | 1.00 | PMP22 (0.86) | PMP22ALOX15BLMKMT2AGRM8 | |
| Glutamine SCHEMBL2443861 | 1.00 | PMP22 (0.86) | PMP22ALOX15BLMKMT2AGRM8 | |
| Glutamine SCHEMBL28971512 | 0.98 | PMP22 (0.83) | PMP22ALOX15BLMKMT2AGRM8 | |
| Glutamine SCHEMBL28756768 | 0.94 | ALOX15 (0.76) | PMP22ALOX15BLMKMT2AGRM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 475 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250134959-A1 | GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-BASED TREATMENTS FOR NEURODEGENERATIVE OR NEUROLOGICAL DISEASES OR DISORDERS | PARTNER THERAPEUTICS, INC. | 2025-05-01 | — | — | US | claimed |
| EP-4475874-A2 | GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-BASED TREATMENTS FOR NEURODEGENERATIVE OR NEUROLOGICAL DISEASES OR DISORDERS | Partner Therapeutics, Inc. (US) | 2024-12-18 | — | — | EP | claimed |
| US-20240361339-A1 | BIOMARKERS FOR PARKINSON'S DISEASE | NATIONAL INSTITUTES OF HEALTH | 2024-10-31 | — | — | US | claimed |
| CN-118660715-A | Granulocyte-macrophage colony stimulating factor-based treatment of neurodegenerative or nervous system diseases or disorders | 合作伙伴治疗有限公司 | 2024-09-17 | — | — | CN | claimed |
| US-20240298641-A1 | COMPOSITION FOR ENHANCING NITROGEN ASSIMILATION IN PLANTS | CH BIOTECH R&D CO., LTD. (TW) | 2024-09-12 | — | — | US | claimed |
| EP-4395893-A1 | BIOMARKERS FOR PARKINSON'S DISEASE | Board of Regents of the University of Nebraska (US) | 2024-07-10 | — | — | EP | claimed |
| CN-118043672-A | Biomarkers for parkinson's disease | 内布拉斯加大学董事会 | 2024-05-14 | — | — | CN | claimed |
| US-20240115539-A1 | ENANTIOMER SELECTIVE ACTION ON NEUROTRANSMISSION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-04-11 | — | — | US | claimed |
| EP-4319735-A1 | ENANTIOMER SELECTIVE ACTION ON NEUROTRANSMISSION | The Board of Trustees of the Leland Stanford Junior University (US) | 2024-02-14 | — | — | EP | claimed |
| CN-117425472-A | Enantioselective action on neurotransmission | 小利兰·斯坦福大学托管委员会 | 2024-01-19 | — | — | CN | claimed |
| US-20040259766-A1 | Bone disorders; administering to mammals, humans, poultry | PROTISTA CORPORATION AB (SE) | 2004-12-23 | — | — | US | claimed |
| EP-1446112-A1 | USE OF GLUTAMATE, GLUTAMATE DERIVATIVES OR METABOLITES, GLUTAMATE ANALOGUES OR MIXTURES THEREOF FOR THE MANUFACTURE OF A COMPOSITION FOR THE TREATMENT OF OSTEOPOROSIS | Essentys AB (SE) | 2004-08-18 | — | — | EP | claimed |
| EP-1370589-A2 | RATIONALLY DESIGNED ANTIBODIES | ALEXION PHARMACEUTICALS, INC. (US) | 2003-12-17 | — | — | EP | claimed |
| WO-2003043626-A1 | USE OF GLUTAMATE, GLUTAMATE DERIVATIVES OR METABOLITES, GLUTAMATE ANALOGUES OR MIXTURES THEREOF FOR THE MANUFACTURE OF A COMPOSITION FOR THE TREATMENT OF OSTEOPOROSIS | ESSENTYS AB (SE) | 2003-05-30 | — | — | WO | claimed |
| US-20030049683-A1 | Immunoglobulin for use in human therapeutics and diagnostics | ALEXION PHARMACEUTICAL, INC. | 2003-03-13 | — | — | US | claimed |
| WO-2003002135-A2 | HERBAL COMPOSITION | PRETORIUS ANDRIES PHILIPPUS (ZA) | 2003-01-09 | — | — | WO | claimed |
| WO-2002046238-A2 | RATIONALLY DESIGNED ANTIBODIES | ALEXION PHARMACEUTICALS, INC. (US) | 2002-06-13 | — | — | WO | claimed |
| CN-1342196-A | Bifidobacterium for the treatment of inflammatory diseases | ENTPR IRELAND (IE) | 2002-03-27 | — | — | CN | claimed |
| EP-0514509-B1 | COMPOSITION AND ITS PREPARATION PROCESS USING ANTIGEN CONJUGATED TO ENZYMATIC ACTIVITY FOR IMMUNOLOGICAL DIAGNOSIS AND CHAGAS' DISEASE IMMUNOLOGICAL DIAGNOSIS KITS, FOR INDIVIDUAL AND EPIDEMIOLOGICAL APPLICATION, BASED ON THAT COMPOSITION | FUNDACAO OSWALDO CRUZ (BR) | 2000-09-20 | — | — | EP | claimed |
| US-4225614-A | Method of treatment for mucocutaneous herpes simplex infections | AKTIEBOLAGET DRACO (SE) | 1980-09-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240298641-A1 | COMPOSITION FOR ENHANCING NITROGEN ASSIMILATION IN PLANTS | AANAT, MTNR1A, MTNR1B | PMP22 4598/4885ALOX15 204/4885BLM 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.